The FDA approved Pfizer's Abrysvo, the first and only RSV vaccine for adults aged 18 to 59 who are at increased risk of severe respiratory illness caused by RSV.
Sniff spikes, the study noted, might help researchers better understand some of the mental issues experienced by covid patients who have lost their sense of smell. Separately, researchers found that ...